Target Price | CHF13.06 |
Price | CHF7.47 |
Potential |
74.78%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target Newron Pharmaceutical 2026 .
The average Newron Pharmaceutical target price is CHF13.06.
This is
74.78%
register free of charge
CHF26.25
251.41%
register free of charge
CHF11.62
55.49%
register free of charge
|
|
A rating was issued by 8 analysts: 7 Analysts recommend Newron Pharmaceutical to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Newron Pharmaceutical stock has an average upside potential 2026 of
74.78%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million CHF | 48.38 | 11.19 |
467.17% | 76.86% | |
EBITDA Margin | 51.30% | -236.70% |
140.67% | 561.38% | |
Net Margin | 30.84% | -280.22% |
117.23% | 1,008.65% |
5 Analysts have issued a sales forecast Newron Pharmaceutical 2025 . The average Newron Pharmaceutical sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Newron Pharmaceutical EBITDA forecast 2025. The average Newron Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Newron Pharmaceutical Analysts have issued a net profit forecast 2025. The average Newron Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share CHF | 0.80 | -1.57 |
193.02% | 296.25% | |
P/E | negative | |
EV/Sales | 16.24 |
5 Analysts have issued a Newron Pharmaceutical forecast for earnings per share. The average Newron Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Newron Pharmaceutical...
Analyst | Rating | Action | Date |
---|---|---|---|
RX SECURITIES |
Locked
➜
Locked
|
Locked | May 11 2025 |
BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
RX SECURITIES |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
RX SECURITIES |
Locked
➜
Locked
|
Locked | Jan 05 2025 |
BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Dec 12 2024 |
Analyst Rating | Date |
---|---|
Locked
RX SECURITIES:
Locked
➜
Locked
|
May 11 2025 |
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Mar 31 2025 |
Locked
RX SECURITIES:
Locked
➜
Locked
|
Mar 31 2025 |
Locked
RX SECURITIES:
Locked
➜
Locked
|
Jan 05 2025 |
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Dec 12 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.